Corrigendum to: 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
A Hein, J Scialla, D Edmonston, L Cooper, A Devore, R Mentz, S Greene, J Butler, N Albert, A Devore, P Sharma, C Duffy, S Shirazian, C Grant, S Mujeeb, S Sharif, P Kumari, M Bhagat, N Beohar, G Ailawadi, L Kotinkaduwa, B Redfors, M Simonato, Z Zhang, Jjv Mcmurray, M Packer, A Desai, J Gong, M Lefkowitz, A Rizkala, M Packer, S Anker, J Butler, G Filippatos, S Pocock, P Carson, F Zannad, J Ferreira, S Pocock, C Zeller, S Anker, J Butler, A Voors, H Mulder, E Reyes, M Cowie, J Lassus, A Hernandez, P Jhund, S Solomon, K Docherty, Hjl Heerspink, I Anand, M Bhm, K Damman, M Gori, B Claggett, P Jhund, M Senni, M Lefkowitz, W Mullens, K Damman, J Testani, P Martens, C Mueller, J Lassus
Abstract
renal dysfunction and its expected course is an important consideration in the evaluation of advanced heart failure therapies such as continuous mechanical support or transplantation. It also pertains to the need for a continuous follow-up of these patients in a heart failure clinic with regular monitoring of renal function, not only to prevent deterioration of renal function but potentially also to seize the chance of using TEER as a strategy to maintain or even extend guideline-directed medical therapy.